Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Cinclus Pharma in connection with listing on Nasdaq Stockholm
Mandate

Vinge advises Cinclus Pharma in connection with listing on Nasdaq Stockholm

June 20, 2024 Intellectual Property Capital Markets and Public M&A Corporate Tax Employment and Benefits IT, Telecommunications and Outsourcing Banking and Finance

Vinge advises Cinclus Pharma Holding AB (publ) (“Cinclus Pharma”) in connection with an offering of new ordinary shares and listing on Nasdaq Stockholm. The first day of trading is 20 June 2024.

The offering will provide Cinclus Pharma with proceeds of approximately SEK 787 million before deduction of issue costs and provided that the over-allotment option is fully exercised. In connection with the offering, Cinclus Pharma also carries out a set-off issue at the offering price to convert outstanding bridge loans. 

Cinclus Pharma is a clinical-stage pharmaceutical company focused on the development of the drug candidate linaprazan glurate, a proprietary “prodrug” of the molecule linaprazan. Linaprazan glurate represents a new and innovative mode of action for the treatment of erosive GERD.

Vinge's team mainly consists of Dain Hård Nevonen,Amanda Knutsson, Anna Svensson,Michaela Ådén and Filip Magnusson (Capital Markets and Public M&A), Stojan Arnestål (IP/Life science), Maria Schultzberg (Corporate taxation), Mathilda Persson (Commercial agreements), Gulestan Ali (Compliance), Nicklas Thorgerzon (IT/GDPR), Jonatan Stentorp (Employment) and Sofia Haggren (Financing).

Related

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025

Vinge advises Advania in connection with the acquisition of atNorth HPC AB

Vinge has advised Advania, one of the leading IT companies in the Nordic region, in connection with the acquisition of atNorth HPC AB. The acquisition strengthens Advania's presence within high-performance computing (HPC).
October 03, 2025